Eli Lilly details TRIUMPH-1 Phase 3 weight-loss outcomes for retatrutide (80 weeks)

Sciencedesk view

Eli Lilly details TRIUMPH-1 Phase 3 weight-loss outcomes for retatrutide (80 weeks)

According to a May 24, 2026 report in The Week, Lilly announced Phase 3 TRIUMPH-1 results for the GIP/GLP-1/GCG tri-agonist retatrutide in adults with obesity o…

READ THE DAY'S DIGEST →

Sports/Healthdesk view

Eli Lilly retatrutide Phase 3-style disclosures: high-dose mean weight loss ~28% over ~80 weeks; GI adverse events common (Nutrition)

The Week health desk (May 24, 2026) reports Lilly’s disclosures for the investigational triple agonist retatrutide, citing roughly 28.3% mean body-weight loss a…

READ THE DAY'S DIGEST →